Jurado José Miguel, Zarcos Irene, Delgado Mayte, Blancas Isabel, Legerén Marta, García-Puche José Luis
Oncology Department, Hospital Clínico Universitario San Cecilio, Avenida, Granada 18012, Spain.
Oncol Lett. 2013 Apr;5(4):1382-1384. doi: 10.3892/ol.2013.1184. Epub 2013 Feb 7.
During the last decade, we have been developing new therapeutic strategies for the treatment of renal cancer, based on knowledge derived from molecular biology. We report a case of long-term renal metastatic cancer progression despite therapy with sunitinib and interleukin, which are the most active drugs in renal cancer. Disease stabilization for 58 weeks was achieved upon sequential use of temsirolimus, following the occurrence of disease progression during angiogenic therapy. The patient demonstrated excellent tolerance without marked symptoms for 10 months. Hypothyroidism and mumps-related adverse events were present. The survival time from diagnosis to lung metastasis was 8 years. Thus, this case demonstrates promising therapeutic effects of the sequential use of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors during different stages of the disease.
在过去十年中，我们一直基于分子生物学知识开发治疗肾癌的新策略。我们报告了一例尽管使用了舒尼替尼和白细胞介素（这两种是肾癌治疗中最有效的药物），但仍出现长期肾转移性癌进展的病例。在血管生成治疗期间疾病进展后，序贯使用替西罗莫司实现了58周的病情稳定。患者在10个月内表现出良好的耐受性，无明显症状。存在甲状腺功能减退和腮腺炎相关的不良事件。从诊断到肺转移的生存时间为8年。因此，该病例证明了在疾病不同阶段序贯使用酪氨酸激酶抑制剂（TKIs）和雷帕霉素靶蛋白（mTOR）抑制剂具有良好的治疗效果。
